doxifluridine has been researched along with epirubicin in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (42.86) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Agata, N; Hirano, S; Iguchi, H; Izumi, H; Mase, T; Takeuchi, T; Tone, H | 1 |
| Furukawa, J; Kinuta, M; Maruhashi, S; Maruyama, H; Masuda, N; Matsui, S; Okamura, J; Ooi, H; Takiguchi, S; Tateishi, H; Tokunaga, M; Yano, H; Yayoi, E | 1 |
| Shin, E; Takatsuka, Y | 1 |
| Fujitake, S; Kataoka, S; Maeda, Y; Nozaki, H; Shimizu, M; Tohyama, M | 2 |
| Kawasaki, K; Kishibuchi, M; Nishi, T; Yagyu, T; Yamasaki, M; Yasui, M; Yayoi, E | 1 |
| Fukuda, Y; Hirao, S; Kinoshita, H; Koyama, I; Mayumi, K; Takatori, H; Terakura, M; Tsukazaki, Y | 1 |
| Beryt, M; Konecny, GE; O'Callaghan, C; Pegram, MD; Pietras, R; Slamon, DJ | 1 |
| Okazaki, Y; Yamada, T; Yuyama, Y | 1 |
| Hamada, K; Kakihara, Y; Kubota, K; Sawada, T; Tagaya, N | 1 |
| Fukami, Y; Hasegawa, H; Hiromatsu, T; Itazu, K; Kawai, K; Komatsu, S; Sakamoto, E; Tabata, T | 1 |
1 review(s) available for doxifluridine and epirubicin
| Article | Year |
|---|---|
[Treatment strategy for recurrent breast cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Floxuridine; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Infusions, Intravenous; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Palliative Care; Survival Rate; Tamoxifen | 1998 |
13 other study(ies) available for doxifluridine and epirubicin
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Antitumor effects of pirarubicin and epirubicin in combination with doxifluridine and cisplatin against mouse P388 leukemia.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Epirubicin; Female; Floxuridine; Leukemia P388; Male; Mice; Mice, Inbred BALB C; Mice, Inbred DBA | 1995 |
[Intra-arterial infusion chemotherapy for liver metastases from breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Medroxyprogesterone; Middle Aged | 1996 |
[A case of giant advanced breast cancer responding remarkably to chemo-endocrine therapy chiefly with doxifluridine].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Floxuridine; Fluorouracil; Humans; Pleural Effusion, Malignant; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 1998 |
[A case of breast cancer with liver metastases responding remarkably to combination therapy of mitoxantrone (MIT), doxifluridine (5'-DFUR) and medroxyprogesterone acetate (MPA)].
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Resistance, Neoplasm; Epirubicin; Female; Floxuridine; Fluorouracil; Humans; Liver Neoplasms; Medroxyprogesterone Acetate; Middle Aged; Mitoxantrone; Tamoxifen | 1999 |
[A case of intra-arterial infusion chemotherapy for liver metastases of breast cancer].
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Papillary; Drug Administration Schedule; Epirubicin; Female; Floxuridine; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Medroxyprogesterone; Middle Aged | 1999 |
[Advanced breast cancer with multiple bone metastases successfully treated with combined chemoendocrine-therapy of CEF (cyclophosphamide, epirubicin, 5-fluorouracil) and 5'-DFUR (5'-deoxy-5-fluorouridine) + MPA (medroxyprogesterone acetate)--a case report
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Epirubicin; Female; Floxuridine; Fluorouracil; Humans; Medroxyprogesterone; Middle Aged; Progesterone Congeners; Treatment Outcome | 2001 |
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Deoxycytidine; Disease Models, Animal; DNA, Neoplasm; Docetaxel; Doxorubicin; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Floxuridine; Gemcitabine; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Paclitaxel; Proto-Oncogene Proteins; Receptor, ErbB-2; Taxoids; Transplantation, Heterologous; Trastuzumab; Tumor Stem Cell Assay; Up-Regulation; Vinblastine; Vinorelbine | 2004 |
[A long-surviving patient with Stage IV breast cancer with no recurrence after combined therapy of medroxy progesterone acetate (MPA) and intra-arterial infusion chemotherapy].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Floxuridine; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Mastectomy, Segmental; Medroxyprogesterone Acetate; Neoplasm Staging; Survivors; Tamoxifen | 2004 |
[Docetaxel (TXT), epirubicin (EPI) and doxifluridine (5'-DFUR) combination neoadjuvant chemotherapy for outpatients with locally advanced breast cancer].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cystadenocarcinoma, Serous; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Floxuridine; Humans; Middle Aged; Preoperative Care; Taxoids | 2004 |
[A case of recurrent breast cancer with multiple lung, adrenal, inferior vena cava tumor thrombus and bone metastases successfully treated with 5'-DFUR and hormonal therapy].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Papillary; Combined Modality Therapy; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Floxuridine; Follow-Up Studies; Humans; Leuprolide; Lung Neoplasms; Mastectomy, Radical; Neoplastic Cells, Circulating; Tamoxifen; Vena Cava, Inferior | 2005 |